Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — H1 2026 Earnings Presentation
21 slides from Arecor Therapeutics's earnings presentation, Oct 12, 2026
Slide 1: Half Year Results 2026 & Fundraise
Half Year Results 2026 & Fundraise October, 12 2026
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Arecor is a clinical-stage biotech company
Arecor is a clinical-stage biotech company, developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Slide 4: Highlights
Highlights Diabetes: Best-in-class, concentrated, ultra-rapid-acting insulins • Addressing unmet patient need in multi-billion $ diabetes market • Designed to enable next generation of longer wear, miniaturised, fully closed loop AID systems • Partnering discussions with multiple insulin pump compan
Slide 5: 1H 2026 Key Financials
1H 2026 Key Financials £M 6 months 6 months to Year to Jun Jun 2025 Ended Dec 2026 (restated) 2025 • 1H 26 partner revenues £0.2 million vs £0.5m 1H 25, reflecting focus on proprietary insulin Revenue 0.2 1.0 1.7 development & strategic partnering • 1H 2025 revenue included £0.5 million AT220 R&D Ex
Slide 6: Arecor's Concentrated Ultra-Rapid Acting Insulins
Arecor’s Concentrated Ultra-Rapid Acting Insulins Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 6 6
Slide 7: Transforming Patient Care for People Living with Diabetes
Transforming Patient Care for People Living with Diabetes Arecor potentially has the only concentrated ultra- rapid acting insulins that can enable pump use for high insulin users and catalyse next generation of longer Algorithm wear smaller AID systems Calculates insulin dose based on CGM CGM readi
Slide 8: The Challenge and Patient Unmet Need
The Challenge and Patient Unmet Need Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 8 8
Slide 9: The challenge that Arecor has overcome
The challenge that Arecor has overcome • As insulin concentration is increased, it slows down its absorption and glucose lowering profile • Arecor has overcome this as demonstrated clinically by AT278 (U500) superior PK/PD profile compared with Humulin-R U500 (U500)* Clinically proven best-in-class,
Slide 10: What Will Drive Growth in the Adoption of AID Systems?
What Will Drive Growth in the Adoption of AID Systems? More Cost Effective Improved Outcomes For patients T1D and T2D who and payer Reduced have high daily Faster insulins enable insulin needs more aggressive Burden algorithms Patients want Cannot achieve 3-day wear Achieve higher Time- smaller, lon
Slide 11: There Are No Concentrated Rapid-Acting Insulins Available for Use in AID Systems
There Are No Concentrated Rapid-Acting Insulins Available for Use in AID Systems Arecor’s platform of concentrated ultra-rapid acting insulins in combination with AID can drive significant adoption U100 insulin AT290 (U200) AT278 (U500) Not designed for high TDD insulin insulin and longer wear in AI
Slide 12: Longer 7-day Wear Currently Not Achievable for Almost All T2Ds
Longer 7-day Wear Currently Not Achievable for Almost All T2Ds and >50% of T1Ds even in largest capacity AID insulin cartridge In AID systems with currently available U100 insulin in a 3mL insulin cartridge % of US IIT T2Ds and T1Ds who CANNOT reach wear-time with the largest 3mL INSULIN PUMP CARTRI
Slide 13: New Era of AID Innovation Driving Need for Arecor's Insulins
New Era of AID Innovation Driving Need for Arecor’s Insulins Omnipod 6 MiniMed Flex Mobi twiist iLet Insulet MiniMed Tandem Sequel Beta Bionics • FDA approval for • 7-day wear US launch: • FDA T2D approval • twiist AID launched • iLet launched May 2023 Omnipod 5 T2D Aug Nov 2022 Feb 2025 Jul 2025 20
Slide 14: Commercial Case
Commercial Case Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 14 14
Slide 15: US Patients with Greatest Unmet Need Represent ~$3Bn Insulin Revenue TAM
US Patients with Greatest Unmet Need Represent ~$3Bn Insulin Revenue TAM today 1st Adopter TAM Open up access ~$3Bn and AID adoption Total Addressab ~$2Bn US tes Patients o le iabe B TAM n II T D ($5 ) 1 million PWDs on >100U/day cannot achieve 3-day 2 million 4 wear in current AID Additional growth
Slide 16: Significant AID Growth Projected in the US and Globally
Significant AID Growth Projected in the US and Globally US AID market still significantly underpenetrated Global AID Market Sales1 US AID market $20bn opportunity $5.7B • Only ~1m PWD on IIT using an AID system in the US today $4.7B $4.0B • 4m PWD on IIT eligible for AID use $3.5B $3.3B $2.9B • Repr
Slide 17: Development & Regulatory Pathway
Development & Regulatory Pathway Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 17 17
Slide 18: Pathway to FDA Regulatory Approval for Concentrated Ultra-Rapid Acting Insulin-AID System
Pathway to FDA Regulatory Approval for Concentrated Ultra- Rapid Acting Insulin-AID System Positive interactions with the FDA confirming innovative Phase 2 clinical study design 2025 2026 2027 2028 2029 2030 Ph 2 CMC Ph 3 CMC BLA CMC &Regs Ph 3 CMC 10x scale up Transfer & 3x File on 3 PV & CTM & CTM
Slide 19: Summary & Outlook
Arecor Summary & Outlook
Slide 20: Outlook
Outlook Best-in-class, concentrated, ultra-rapid-acting insulins • Addressing unmet patient need in multi-billion $ diabetes market • Designed lowering burden and improving outcomes by transforming Automated Insulin Delivery (AID) systems Opportunity to partner with multiple major insulin pump compa
Slide 21: Thank You
Thank You Dr Sarah Howell, CEO David Ellam, CFO Chesterford Research Park Little Chesterford CB10 1XL +44 1223 426 060 [email protected] www.arecor.com